DAUNOXOME LIPOSOMAL - IV 2MG/ML, 50MG/VIAL 2 MG — DIN 02218046
DAUNORUBICIN : 2 MG · GILEAD SCIENCES INC · SUSPENSION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is DAUNOXOME LIPOSOMAL - IV 2MG/ML, 50MG/VIAL?
DAUNOXOME LIPOSOMAL - IV 2MG/ML, 50MG/VIAL 2 MG contains DAUNORUBICIN : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02218046, held by GILEAD SCIENCES INC, supplied as SUSPENSION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 21-Sep-2001. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is DAUNOXOME LIPOSOMAL - IV 2MG/ML, 50MG/VIAL used for?
null
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Daunorubicin cost around the world?
Daunorubicin is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Iceland publishes a max wholesale; Norway publishes a max AUP (pharmacy retail). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 1 | 4 | AUD███.██ |
| Iceland | max wholesale | 3 | 3 | ISK███.██ |
| Saudi Arabia | public | 2 | 2 | SAR███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 1 | NOK███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
11 pack listings across 8 brand entries and 5 price bases, refreshed 08 Sep 2026. Ranges span every Daunorubicin pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Daunorubicin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Daunorubicin, across 6 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| GENERIC MEDICAL PARTNERS INC | 2 | 1 | DAUNORUBICIN INJECTABLE SOLUTION | Sourceable in Canada |
| HIKMA CANADA LIMITED | 1 | 1 | DAUNORUBICIN HYDROCHLORIDE INJECTION | Sourceable in Canada |
| SEARCHLIGHT PHARMA INC | 1 | 1 | CERUBIDINE | Sourceable in Canada |
| GILEAD SCIENCES INC | 1 | 0 | DAUNOXOME LIPOSOMAL - IV 2MG/ML, 50MG/VIAL | No marketed DIN |
| TEVA CANADA LIMITED | 1 | 0 | DAUNORUBICIN HYDROCHLORIDE FOR INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2 MG |
|---|---|
| Dosage form | SUSPENSION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | null |
| Storage | null |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Daunorubicin |
|---|---|
| ATC code | L01DB02 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02218046 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2218046 |
| Brand name | DAUNOXOME LIPOSOMAL - IV 2MG/ML, 50MG/VIAL |
| Generic / active ingredient | DAUNORUBICIN : 2 MG |
| Market authorization holder | GILEAD SCIENCES INC |
| Health Canada schedule | Prescription |
| ATC code | L01DB02 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01DB |
| Current status | CANCELLED POST MARKET |
| Status date | 21-Sep-2001 |
| Original market date | 1997-09-22 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Anaerobic infections: 500 mg every 8 hours. Trichomoniasis: Single 2 g dose or 250 mg TID for 7 days. Amebiasis: 500-750 mg TID for 5-10 days. Administer with food.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to metronidazole, nitroimidazole derivatives, or any ingredient in the formulation. Contraindicated in the first trimester of pregnancy.
Warnings and precautions
Potential for neurological effects (convulsive seizures, peripheral neuropathy). Use with caution in patients with CNS diseases. Risk of severe hepatotoxicity in Cockayne syndrome.
Is Daunorubicin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by HIKMA CANADA LIMITED, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for DAUNOXOME LIPOSOMAL - IV 2MG/ML, 50MG/VIAL
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 6 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CERUBIDINE | 20 MG | POWDER FOR SOLUTION | SEARCHLIGHT PHARMA INC | MARKETED | 01926683 |
| DAUNORUBICIN HYDROCHLORIDE INJECTION | 20 MG / 4 ML | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02539209 |
| DAUNORUBICIN INJECTABLE SOLUTION | 50 MG / 10 ML | SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | 02501481 |
| DAUNORUBICIN HYDROCHLORIDE FOR INJECTION | 20 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | 02231420 |
| DAUNORUBICIN INJECTABLE SOLUTION | 20 MG / 4 ML | SOLUTION | GENERIC MEDICAL PARTNERS INC | APPROVED | 02501473 |
2 · Same class — other molecules in ATC L01DB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Doxorubicin | ADRIAMYCIN PFS · ADRIAMYCIN RDF · ADRIAMYCIN RDF INJ 10MG/VIAL · ADRIAMYCIN RDF INJ 150MG/VIAL · +13 more | 25 | 7 | Yes |
| Daunorubicin | CERUBIDINE · DAUNORUBICIN HYDROCHLORIDE FOR INJECTION · DAUNORUBICIN HYDROCHLORIDE INJECTION · DAUNORUBICIN INJECTABLE SOLUTION · +1 more | 6 | 3 | Yes |
| Epirubicin | EPIRUBICIN FOR INJECTION · EPIRUBICIN HYDROCHLORIDE FOR INJECTION · EPIRUBICIN HYDROCHLORIDE INJECTION · PHARMORUBICIN PFS · +3 more | 15 | 1 | Yes |
| Idarubicin | AJ-IDARUBICIN · IDAMYCIN - CAP 10MG · IDAMYCIN - CAP 25MG · IDAMYCIN - CAP 5MG · +7 more | 12 | 1 | Yes |
| Mitoxantrone | MITOXANTRONE INJECTION · MITOXANTRONE INJECTION USP · NOVANTRONE · NOVANTRONE INJ 2MG/ML | 5 | 1 | Yes |
| Valrubicin | VALTAXIN | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01DC | Bleomycin · Mitomycin | 13 | 5 |
| L01DA | Dactinomycin | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DAUNOXOME LIPOSOMAL - IV 2MG/ML, 50MG/VIAL called?
The same molecule, Daunorubicin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Vyxeos | Latin | Australia, Saudi Arabia |
| Daunoblastin | Latin | Iceland, South Africa |
| Cerubidin | Latin | Iceland |
| Daunorubicin | Latin | Iceland |
| Vyxeos liposomal | Latin | Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.